Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 24-Apr-24 4:18 PM View:  | Moore Timothy L. Chief Technical Officer | Allogene Therapeutics, Inc. (ALLO) | 22-Apr-24 | Payment of Exercise | 17,360 | $3.47 | $60,188.90 | (6%) 282.82K to 265.46K | |
| 18-Mar-24 8:10 PM View: | Chang David D President and CEO Director | Allogene Therapeutics, Inc. (ALLO) | 14-Mar-24 | Payment of Exercise | 53,393 | $4.33 | $231,192.00 | (< 1%) 7.43M to 7.38M | |
| 06-Mar-24 10:00 PM View: | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Allogene Therapeutics, Inc. (ALLO) | 30-Jan-24 | Private Purchase | 190 | $3.60 | $683.05 | < 1% 819.4K to 819.59K | |
| 31-Jan-24 5:45 PM View: | Roberts Zachary EVP of R&D | Allogene Therapeutics, Inc. (ALLO) | 25-Jan-24 | Grant | 140,000 | -- | -- | 37% 375.25K to 515.25K | |
| 31-Jan-24 5:46 PM View: | Belldegrun Arie Director | Allogene Therapeutics, Inc. (ALLO) | 25-Jan-24 | Grant | 211,973 | -- | -- | 3% 8.36M to 8.57M | |
| 31-Jan-24 5:47 PM View: | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Allogene Therapeutics, Inc. (ALLO) | 25-Jan-24 | Grant | 29,400 | -- | -- | 4% 790.0K to 819.4K | |
| 31-Jan-24 5:42 PM View: | Chang David D President and CEO Director | Allogene Therapeutics, Inc. (ALLO) | 25-Jan-24 | Grant | 317,800 | -- | -- | 4% 7.11M to 7.43M | |
| 31-Jan-24 5:51 PM View: | Moore Timothy L. Chief Technical Officer | Allogene Therapeutics, Inc. (ALLO) | 25-Jan-24 | Grant | 96,600 | -- | -- | 52% 186.22K to 282.82K | |
| 31-Jan-24 5:48 PM View: | Douglas Earl Martin SVP, General Counsel | Allogene Therapeutics, Inc. (ALLO) | 25-Jan-24 | Grant | 41,800 | -- | -- | 10% 435.83K to 477.63K | |
| 24-Jan-24 5:25 PM View: | Roberts Zachary EVP of R&D | Allogene Therapeutics, Inc. (ALLO) | 22-Jan-24 | Payment of Exercise | 24,690 | $3.17 | $78,375.90 | (6%) 399.94K to 375.25K | |
| 20-Dec-23 4:26 PM View: | Messemer Deborah M. Director | Allogene Therapeutics, Inc. (ALLO) | 18-Dec-23 | Sale (Planned) | 18,640 | $2.70 | $50,316.80 | (23%) 81.1K to 62.46K | |
| 17-Oct-23 5:02 PM View: | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Allogene Therapeutics, Inc. (ALLO) | 16-Oct-23 | Grant | 790,000 | -- | -- | 100% 0 to 790.0K | |
| 17-Aug-23 6:57 PM View: | Douglas Earl Martin GENERAL COUNSEL | Allogene Therapeutics, Inc. (ALLO) | 14-Aug-23 | Grant | 435,834 | -- | -- | 100% 0 to 435.83K | |
| 14-Aug-23 7:59 PM View: | Chen Yinlin Jack SVP, Finance | Allogene Therapeutics, Inc. (ALLO) | 10-Aug-23 | Grant | 11,401 | -- | -- | 15% 77.48K to 88.88K | |
| 09-Aug-23 4:07 PM View: | Mayo Stephen Director | Allogene Therapeutics, Inc. (ALLO) | 07-Aug-23 | Sale | 10,000 | $4.29 | $42,855.00 | (28%) 35.33K to 25.33K | |
| 15-Jun-23 5:02 PM View: | Sato Vicki L Director | Allogene Therapeutics, Inc. (ALLO) | 13-Jun-23 | Grant | 59,649 | -- | -- | 144% 41.45K to 101.1K | |
| 15-Jun-23 5:01 PM View: | Humer Franz B Director | Allogene Therapeutics, Inc. (ALLO) | 13-Jun-23 | Grant | 74,561 | -- | -- | 39% 191.89K to 266.45K | |
| 15-Jun-23 5:06 PM View: | Messemer Deborah M. Director | Allogene Therapeutics, Inc. (ALLO) | 13-Jun-23 | Grant | 74,561 | -- | -- | 1141% 6.54K to 81.1K | |
| 15-Jun-23 5:00 PM View: | Witte Owen N. Director | Allogene Therapeutics, Inc. (ALLO) | 13-Jun-23 | Grant | 74,561 | -- | -- | 34% 218.27K to 292.83K | |
| 26-Apr-23 5:20 PM View: | Moore Timothy L. Chief Technical Officer | Allogene Therapeutics, Inc. (ALLO) | 24-Apr-23 | Grant | 186,219 | -- | -- | 100% 0 to 186.22K | |
| 05-Apr-23 6:43 PM View: | Smith Lillian VP, Corporate Counsel | Allogene Therapeutics, Inc. (ALLO) | 01-Apr-23 | Grant | 56,545 | -- | -- | 67% 83.84K to 140.39K | |
| 24-Mar-23 8:19 PM View: | Moore Alison Chief Technical Officer | Allogene Therapeutics, Inc. (ALLO) | 22-Mar-23 | Grant | 558,094 | -- | -- | 487% 114.64K to 672.73K | |
| 24-Mar-23 8:13 PM View: | Chang David D President and CEO Director | Allogene Therapeutics, Inc. (ALLO) | 22-Mar-23 | Grant | 1,924,460 | -- | -- | 37% 5.18M to 7.11M | |
| 24-Mar-23 8:16 PM View: | Roberts Zachary EVP of R&D | Allogene Therapeutics, Inc. (ALLO) | 22-Mar-23 | Grant | 148,035 | -- | -- | 59% 251.91K to 399.94K | |
| 24-Mar-23 8:14 PM View: | Belldegrun Arie Director | Allogene Therapeutics, Inc. (ALLO) | 22-Mar-23 | Grant | 1,282,980 | -- | -- | 18% 7.08M to 8.36M | |
| 24-Mar-23 8:17 PM View: | Schmidt Eric Thomas Chief Financial Officer | Allogene Therapeutics, Inc. (ALLO) | 22-Mar-23 | Grant | 558,094 | -- | -- | 38% 1.46M to 2.02M | |
| 16-Mar-23 10:00 PM View: | Chang David D President and CEO Director | Allogene Therapeutics, Inc. (ALLO) | 14-Mar-23 | Payment of Exercise | 22,340 | $5.56 | $124,210.00 | (< 1%) 5.2M to 5.18M | |
| 16-Mar-23 10:00 PM View: | Schmidt Eric Thomas Chief Financial Officer | Allogene Therapeutics, Inc. (ALLO) | 14-Mar-23 | Payment of Exercise | 35,879 | $5.47 | $196,258.00 | (2%) 1.49M to 1.46M | |
| 16-Mar-23 10:00 PM View: | Moore Alison Chief Technical Officer | Allogene Therapeutics, Inc. (ALLO) | 14-Mar-23 | Payment of Exercise | 8,351 | $5.51 | $45,989.80 | (7%) 122.99K to 114.64K | |
| 16-Mar-23 10:00 PM View: | Bhavnagri Veer General Counsel | Allogene Therapeutics, Inc. (ALLO) | 14-Mar-23 | Payment of Exercise | 23,628 | $5.67 | $133,971.00 | (4%) 579.68K to 556.05K | |
| 14-Feb-23 5:10 PM View: | Bhavnagri Veer General Counsel | Allogene Therapeutics, Inc. (ALLO) | 13-Feb-23 | Sale | 3,000 | $6.85 | $20,550.00 | (< 1%) 580.68K to 577.68K | |
| 24-Jan-23 5:02 PM View: | Roberts Zachary EVP of R&D | Allogene Therapeutics, Inc. (ALLO) | 20-Jan-23 | Grant | 251,908 | -- | -- | 100% 0 to 251.91K | |
| 18-Jan-23 6:10 PM View: | Bhavnagri Veer General Counsel | Allogene Therapeutics, Inc. (ALLO) | 17-Jan-23 | Sale (Planned) | 3,000 | $7.04 | $21,120.00 | (< 1%) 583.68K to 580.68K | |
| 19-Dec-22 4:29 PM View: | Bhavnagri Veer General Counsel | Allogene Therapeutics, Inc. (ALLO) | 15-Dec-22 | Sale (Planned) | 5,602 | $7.53 | $42,186.40 | (< 1%) 589.28K to 583.68K | |
| 11-Oct-22 4:35 PM View: | Amado Rafael EVP of R&D | Allogene Therapeutics, Inc. (ALLO) | 07-Oct-22 | Payment of Exercise | 8,464 | $11.83 | $100,099.00 | (2%) 550.41K to 541.95K | |
| 11-Oct-22 4:35 PM View: | Amado Rafael EVP of R&D | Allogene Therapeutics, Inc. (ALLO) | 07-Oct-22 | Grant | 19,120 | -- | -- | 4% 531.29K to 550.41K | |
| 05-Oct-22 4:02 PM View: | Amado Rafael EVP of R&D | Allogene Therapeutics, Inc. (ALLO) | 03-Oct-22 | Payment of Exercise | 8,968 | $11.06 | $99,201.30 | (2%) 540.26K to 531.29K | (10%) |
| 15-Aug-22 5:40 PM View: | Witte Owen N. Director | Allogene Therapeutics, Inc. (ALLO) | 12-Aug-22 | Sale Duplicate | 5,000 | $17.25 | $86,250.00 | (2%) 223.27K to 218.27K | |
| 15-Aug-22 5:12 PM View: | Witte Owen N. Director | Allogene Therapeutics, Inc. (ALLO) | 12-Aug-22 | Sale | 5,000 | $17.25 | $86,250.00 | (2%) 223.27K to 218.27K | |
| 15-Aug-22 5:40 PM View: | Witte Owen N. Director | Allogene Therapeutics, Inc. (ALLO) | 11-Aug-22 | Private Sale Duplicate | 10,000 | $16.50 | $165,000.00 | (4%) 233.27K to 223.27K | |
| 15-Aug-22 5:12 PM View: | Witte Owen N. Director | Allogene Therapeutics, Inc. (ALLO) | 11-Aug-22 | Private Sale | 10,000 | $16.50 | $165,000.00 | (4%) 233.27K to 223.27K | |
| 02-Aug-22 5:40 PM View: | Amado Rafael EVP of R&D and CMO | Allogene Therapeutics, Inc. (ALLO) | 02-Aug-22 | Market Sale (Planned) | 2,000 | $11.97 | $23,940.00 | (< 1%) 542.26K to 540.26K | (2%) |
| 12-Jul-22 4:48 PM View: | Mayo Stephen Director | Allogene Therapeutics, Inc. (ALLO) | 08-Jul-22 | Grant | 35,328 | -- | -- | 100% 0 to 35.33K | |
| 06-Jul-22 4:16 PM View: | Amado Rafael EVP of R&D and CMO | Allogene Therapeutics, Inc. (ALLO) | 05-Jul-22 | Market Sale (Planned) | 2,000 | $11.44 | $22,880.00 | (< 1%) 544.26K to 542.26K | (7%) |
| 23-Jun-22 4:40 PM View: | Witte Owen N. Director | Allogene Therapeutics, Inc. (ALLO) | 22-Jun-22 | Market Sale | 10,000 | $11.76 | $117,600.00 | (4%) 243.27K to 233.27K | (4%) |
| 22-Jun-22 4:47 PM View: | Amado Rafael EVP of R&D and CMO | Allogene Therapeutics, Inc. (ALLO) | 21-Jun-22 | Market Sale (Planned) | 2,000 | $11.18 | $22,360.00 | (< 1%) 546.26K to 544.26K | (9%) |
| 17-Jun-22 4:58 PM View: | Kazam Joshoa A Director | Allogene Therapeutics, Inc. (ALLO) | 15-Jun-22 | Grant | 44,178 | -- | -- | 17% 258.88K to 303.06K | |
| 17-Jun-22 4:58 PM View: | Humer Franz B Director | Allogene Therapeutics, Inc. (ALLO) | 15-Jun-22 | Grant | 44,178 | -- | -- | 30% 147.71K to 191.89K | |
| 17-Jun-22 4:58 PM View: | Sato Vicki L Director | Allogene Therapeutics, Inc. (ALLO) | 15-Jun-22 | Grant | 22,089 | -- | -- | 114% 19.36K to 41.45K | |
| 17-Jun-22 4:58 PM View: | Witte Owen N. Director | Allogene Therapeutics, Inc. (ALLO) | 15-Jun-22 | Grant | 22,089 | -- | -- | 10% 221.18K to 243.27K |
